‘How I do’ CMR in HCM Dr Sanjay Prasad, Royal Brompton Hospital

Slides:



Advertisements
Similar presentations
How we do….. CMR of the Coronaries Arteries Gavin Bainbridge, Sven Plein, John Greenwood CMR Clinical Research Group Leeds General Infirmary, UK
Advertisements

CMR of Non-ischemic Dilated and Restrictive Cardiomyopathies
‘How I do’ CMR in DCM Dr Sanjay Prasad, Royal Brompton Hospital London, UK. For SCMR August 2006 This presentation is posted for members of scmr as an.
David A. Bluemke, M.D., Ph.D. Associate Professor, Clinical Director, MRI Departments of Radiology and Medicine Johns Hopkins University School of Medicine.
“How we do” CMR in acute myocardial infarction Derek J Hausenloy, Anna S Herrey, James C Moon UCLH Heart Hospital and The Hatter Institute, University.
Echocardiographic Assessment of LV Systolic Function
‘How I do’ CMR in HCM Dr Sanjay Prasad, Royal Brompton Hospital London, UK. For SCMR August 2006 This presentation is posted for members of scmr as an.
Hypertrophic Cardiomyopathy Guidelines Summary from the: ACC/ESC Clinical Expert Consensus Statement on Hypertrophic Cardiomyopathy Maron BJ, et al. J.
‘How I do’ CMR in valvular heart disease Dr. Saul Myerson Clinical Lecturer in Cardiovascular Medicine For 02/2007 This presentation posted.
 Genetic disease of heart muscle characterized by left ventricular hypertrophy in absence of another cardiac or systemic disease; variable morphologies.
Atrial and Ventricular Hypertrophy. ECG Features and Common Causes.
CMR-Based Differentiation of AL and ATTR Cardiac Amyloidosis February 2014,JACC.
How I do CMR Myocardial Perfusion imaging SCMR Website 2006 Christopher Klassen MD, PHD University of Florida Health Science Center Dr. Norbert Wilke This.
Introduction BACKGROUND  N on-sustained VT (NSVT) is a known risk factor for poor outcomes in adults with HCM and diastolic dysfunction is linked to poor.
Adult Echocardiography Lecture 10 Coronary Anatomy
 R40: 30 yo man found unconscious, on ambo arrival VT. ROSC after single DC shock  In ED conscious, mildly intoxicated  Normal bloods, CXR, alcohol.
“How I do” a CMR Volume study
Date of download: 5/31/2016 Copyright © 2016 McGraw-Hill Education. All rights reserved. Evaluation of the patient with known or suspected ischemic heart.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pregnancy in Patients With Pre-Existing Cardiomyopathies.
A Typical Cardiac MRI Study
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical Features of Hypertrophic Cardiomyopathy.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Diagnostic Value of CMR in Patients With Biomarker-Positive.
Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Frequency and clinical expression of cardiac troponin.
Mechanisms and Treatment of Symptoms in Hypertrophic Cardiomyopathy: Septal Reduction Therapy or Nothing? Andrew Wang, MD, FACC, FAHA Associate Professor.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Fibrosis With Mortality and Sudden.
“How we do….. CMR of the Coronaries Arteries”
“How we do” CMR in acute myocardial infarction
Characterisation of Myocardial Injury via T1 Mapping in Early Reperfused Myocardial Infarction and its Relationship with Global and Regional Diastolic.
A Case of Elderly Women with Biventricular Hypertrophic Cardiomyopathy
‘How I do’ CMR in valvular heart disease
‘How I do’: CMR of repaired tetralogy of Fallot
‘How I do’ CMR in DCM Dr Sanjay Prasad, Royal Brompton Hospital
Obstructive Hypertrophic Cardiomyopathy
How I do CMR Myocardial Perfusion imaging
Utility of Cardiac MRI in Diagnosing Fabry’s Cardiomyopathy
by Thomas H. Marwick, and Markus Schwaiger Circ Cardiovasc Imaging
Circ Cardiovasc Imaging
Interpreting Cardiac Echo Reports
Figure 10 Assessment of myocardial fibrosis
HYPERTROPHIC CARDIOMYOPATHY(HCM)
New Developments in Hypertrophic Cardiomyopathy
Figure 1 Cine cardiovascular magnetic resonance (CMR)
Rodney H. Falk et al. JACC 2016;68:
Nat. Rev. Cardiol. doi: /nrcardio
Figure 6 Risk stratification in hypertrophic cardiomyopathy (HCM)
Recommendations on the Echocardiographic Assessment of Aortic Valve Stenosis: A Focused Update from the European Association of Cardiovascular Imaging.
“How I do” a CMR Volume study
SAM.
Prevalence and clinical significance of acquired left coronary artery fistulas after surgical myectomy in patients with hypertrophic cardiomyopathy  Aurelio.
Myocardial Perfusion, Scarring, and Function in Anomalous Left Coronary Artery From the Pulmonary Artery Syndrome: A Long-Term Analysis Using Magnetic.
Nat. Rev. Cardiol. doi: /nrcardio
Figure 5 Genotype-positive hypertrophic
Figure 2 Apical hypertrophy missed by echocardiography
Hypertrophic Cardiomyopathy in Childhood: Disease Natural History, Impact of Obstruction, and Its Influence on Survival  Edward J. Hickey, MD, Brian W.
AORTIC VALVE Aortic Valve is located at the junction of LV outflow tract and ascending Aorta. Aortic valve consists of 3 components – annulus, cusp and.
International Journal of Cardiology
Echocardiographic Assessment of Left Ventricular Systolic Function: An Overview of Contemporary Techniques, Including Speckle-Tracking Echocardiography 
Hiroo Takayama, MD, PhD, Wendy K. Chung, MD, PhD, Mathew S
Nat. Rev. Cardiol. doi: /nrcardio
Slides courtesy of Dr. Randall Harada
Volume 13, Issue 1, Pages (January 2016)
Bar chart of cardiac volumes and EF in the healthy individuals, HCM LVH− patients and HCM LVH+ patients. Blue bars show the indexed diastolic volumes (EDVI.
Deep Learning for Diagnosis of Chronic Myocardial Infarction on Nonenhanced Cardiac Cine MRI Deep learning to identify myocardial infarction on nonenhanced.
Examples of association between CMR features and abnormal Q waves.
Ronan Abgral et al. JIMG 2017;10:
Scatter plot of relationship between MWT, GLS and EF upper panel shows that GLS was closely related to MWT with worse LV function by GLS correlating to.
Fig. 7. T1 mapping in dilated cardiomyopathy (DCM)
Dee Dee Wang et al. JIMG 2016;9:
Illustration of discordance between location of Q waves on ECG derivations and location of LGE in the myocardium on CMR. (A) Incidence of LGE within cited.
Figure 1 Flowchart illustrating numbers of cases evaluated at each stage of study. SADS, sudden arrhythmic death ... Figure 1 Flowchart illustrating numbers.
Presentation transcript:

‘How I do’ CMR in HCM Dr Sanjay Prasad, Royal Brompton Hospital London, UK. For SCMR August 2006 This presentation is posted for members of scmr as an educational guide – it represents the views and practices of the author, and not necessarily those of SCMR. s.prasad@rbht.nhs.uk

Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy: Clinical Aspects Characterized by myocyte disarray, hypertrophy, and interstitial fibrosis 90% of pts have familial disease 10% de novo mutations Increased risk of SCD Adult prevalence 1:500 (Autosomal Dominant) 1st degree-relatives -1:2 risk gene carrier

HCM: Diagnosis Unexplained hypertrophy Measured wall thickness exceeds 2SD for gender-,age-, and BSA-matched populations ≥ 1.5cm in absence of a recognized cause There may be associated systolic anterior motion of the mitral valve leaflets and outflow tract obstruction Multiple causative mutations in at least 10 different sarcomeric proteins Variable phenotype and clinical outcome Seidman et al 2002; Chien 2003

HCM – Histopathology Myocyte Disarray Here with some associated fibrosis

HCM and Fibrosis In addition to asymmetric hypertrophy, there is often extensive fibrosis

HCM: SAM + LVOTO ADD DCM Cine

CMR Evaluation of HCM The first important aspect is determining LV and RV volumes, ejection fractions, maximal wall thickness and mass We recommend the modified Simpson’s method rather than biplanar assessment since it makes no assumptions on cardiac morphology and is both more accurate and reproducible. After piloting the 4ch and VLA views, retrospectively gated gradient echo cine slices are taken from the base to apex Typically 7mm slices with a 3mm gap. Usually myocardial coverage is achieved in 9-10 slices

CMR Quantification See the presentation ‘how I do’ LV volumes Downloadable from www.scmr.org

HCM: Cine Imaging The key questions to address are: - Presence, distribution, and severity of LVH and RVH. LV/RV mass and wall thickness Extent of septal involvement Distribution of hypertrophy in the variant forms of hypertrophic cardiomyopathy

Functional Assessment Cine images are then acquired to determine if there is SAM and LVOTO. SSFP images with retrospective gating recommended

HCM: LVOTO Assessment In-plane followed by through plane breath-hold flow mapping is performed to look at the peak velocity at the outflow tract (red-bar) and at the level of the aortic valve.

Assessment of Fibrosis The presence of replacement fibrosis can be detected using the inversion recovery late enhancement technique following gadolinium-DTPA administration. After all, fibrosis is the main component of chronic MI which is visible with the late enhancement technique

Fibrosis imaging in HCM Gd infarct imaging HCM fibrosis imaging?

HCM – a wide variety of scar 2 patients. For the lower patient, scar is present and invisible without Gd-DTPA. Many patients have no detectable scar

Fibrosis -not like IHD Picro sirius red stains collagen red. In-vivo vs exvivo match

Detection of Fibrosis: Inversion Recovery Sequence Dosage of Gd-DTPA: 0.1-0.2mmol/kg At 0.1mmol/kg, images are usually acquired after about 5 minutes with a TI starting at ~340ms (every other heart beat). At 0.2 mmol/kg, scans are acquired after about 15 minutes with a TI starting at ~250ms.

HCM: Detection of Fibrosis LGE is predominantly seen in a patchy distribution and correlates with wall thickness. Unlike in IHD, the subendocardium is not necessarily affected. Unlike DCM, the distribution is typically more diffuse and not specific to mid-wall circumferential fibres.

Detection of Fibrosis: Inversion Recovery Sequence Tips to confirm fibrosis and not artefact: Phase swap each slice If mid-wall enhancement is seen, ensure TI is optimal and if need be, repeat the slice with a different TI Cross-cut through any areas of suspected mid-wall enhancement If subendocardial enhancement is seen, reconsider the diagnosis or assess if this reflects ‘bystander’ coronary disease It is common to see some fibrosis around the LVOT and at the RV/LV septal insertion points

Assessment of Fibrosis late enhancement in the septum reflecting fibrosis

RV insertion point enhancement 2 spots of enhancement at RV insertion points The 3rd point is artefact – Present AP phase encoding, disappears head-foot. This is artefact ghosting across the image.

Other techniques: perfusion Rest Perf Late Gd Perfusion defects in HCM – uncertain significance; here matching enhancement

Summary Evaluate function, volumes, maximal wall thickness, distribution of hypertrophy and overall mass index. Flow mapping to assess LVOTO Presence of fibrosis important using inversion-recovery Gd-DTPA s.prasad@rbht.nhs.uk